现代主动监测时代确诊GG1前列腺癌的自然史
该研究基于加州大学旧金山分校泌尿科结局数据库,纳入1429例确诊为GG1前列腺癌并接受主动监测的男性,评估活检升级、转移和死亡等结局。10年升级率和重大升级率分别为62%和19%,转移率1.9%、全因死亡率3.4%、前列腺癌特异性死亡率0.1%;5年升级后积极治疗率73%。多因素分析显示年龄、阳性针数百分比和PSA密度与升级风险显著相关,而mpMRI阳性或变化及高风险基因组评分未显示关联。
要点
- 确诊GG1前列腺癌主动监测10年活检升级率62%,重大升级率19%。
- 10年转移率1.9%、全因死亡率3.4%、前列腺癌特异性死亡率0.1%。
- 年龄、阳性针数百分比和PSA密度与升级风险显著相关。
核心结论
- 确诊GG1前列腺癌患者主动监测下10年升级率高但转移和死亡率低,支持主动监测的适当性。
- 高风险基因组评分及mpMRI阳性或变化与升级结局无关,需进一步优化。
研究设计与样本
- 回顾性队列研究,查询加州大学旧金山分校泌尿科结局数据库。
- 纳入1429例确诊为GG1前列腺癌的男性。
- 主要结局为活检升级(≥GG2,Gleason≥3+4),次要结局包括重大升级(≥GG3,Gleason≥4+3)、转移、死亡、前列腺癌特异性死亡及升级后积极治疗。
- 采用生命表估计、Kaplan-Meier分析和多因素Cox比例风险回归模型。
主要发现
- 10年升级率和重大升级率分别为62%和19%。
- 10年转移率、全因死亡率和前列腺癌特异性死亡率分别为1.9%、3.4%和0.1%。
- 5年升级后积极治疗率为73%。
- 多因素回归分析中,年龄增加、阳性针数百分比和前列腺特异性抗原密度与升级风险显著相关。
- mpMRI阳性、mpMRI变化或高风险基因组评分与升级风险无显著关联。
临床怎么用
- 确诊GG1前列腺癌患者可考虑主动监测,因10年转移和死亡率低。
- 年龄、阳性针数百分比和PSA密度可用于评估升级风险。
- 高风险基因组评分和mpMRI结果在升级风险分层中的价值需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Grade group 1 (GG1, Gleason 3 + 3) prostate cancer (PCa) is considered low risk but can upgrade, and is managed with active surveillance (AS). Amidst recent controversy of whether GG1 PCa should be called cancer, we determined the nature of progression of GG1 disease in a modern AS cohort with multiparametric magnetic resonance imaging (mpMRI) and genomic testing. METHODS: The Urologic Outcomes Database at the University of California San Francisco was queried for men with confirmed GG1 PCa. The primary outcome was biopsy upgrade (≥GG2, Gleason ≥3 + 4). The secondary outcomes included major upgrade (≥GG3, Gleason ≥4 + 3), metastasis, mortality, PCa-specific mortality, and active treatment after upgrade. Life table estimates, Kaplan-Meier analyses, and multivariable Cox proportional hazards regression models were performed. KEY FINDINGS AND LIMITATIONS: A total of 1429 men met the inclusion criteria. The 10-yr rates of upgrade and major upgrade were 62% and 19%, respectively. The 10-yr rates of metastasis, mortality, and PCa-specific mortality were 1.9%, 3.4%, and 0.1%, respectively. The 5-yr rate of active treatment after upgrade was 73%. On multivariable regression analyses, increasing age, percentage of positive cores, and prostate-specific antigen density, but not positive mpMRI, change in mpMRI, or high-risk genomics, were significantly associated with the risk of upgrade. Upgrade to ≥GG3 was the only factor associated with advancement to active treatment. CONCLUSIONS AND CLINICAL IMPLICATIONS: Men with confirmed GG1 PCa on AS have high rates of upgrade, and low rates of metastasis and mortality at 10 yr, confirming the appropriateness of AS. A high-risk genomic score, and initial positive mpMRI or change in mpMRI were not associated with upgrade outcomes, requiring further optimization.
引用
- Shee K, Song JJ, Cowan JE, et al. The Natural History of Confirmed Grade Group 1 Prostate Cancer Managed with Active Surveillance in the Modern Era. Eur Urol Oncol. 2025. PMID: 40619326. doi:10.1016/j.euo.2025.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。